At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 10 enrolled

Drug / intervention

Anakinradrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02547766

NCT02547766Phase 2Completed

Compare CT.gov

Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices

University of Utah·interventional·Posted Sep 11, 2015·Updated Feb 17, 2020

In Brief

A Phase 2 clinical trial evaluating Anakinra for Heart Failure. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Heart failure remains a major cause of morbidity and mortality. Many patients with heart failure receive support from a left ventricular assist device (LVAD) at some point in the course of their disease. Some of these LVAD patients experience a durable recovery after ventricular unloading with an LVAD, which may be associated with inhibition of inflammatory cytokines. This small pilot study aims to determine the biologic and clinical efficacy of an interleukin-1 receptor antagonist (Anakinra) at inducing myocardial recovery in patients supported with left ventricular assist devices.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHeart Failure

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartApr 2015

First PostedSep 2015

Primary CompletionDec 2016

TodayJul 2026

First PostedSep 11, 2015

Enrollment StartApr 1, 2015

Primary CompletionDec 1, 2016

TodayJul 2, 2026

Enrollment to primary: 1.7 yearsPosted 10.8 years ago

Interventions

Anakinradrug

Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.